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ScienceDirectProtein aggregation occurs through a variety of mechanisms,
initiated by the unfolded, non-native, or even the native state
itself. Understanding the molecular mechanisms of protein
aggregation is challenging, given the array of competing
interactions that control solubility, stability, cooperativity and
aggregation propensity. An array of methods have been
developed to interrogate protein aggregation, spanning
computational algorithms able to identify aggregation-prone
regions, to deep mutational scanning to define the entire
mutational landscape of a protein’s sequence. Here, we review
recent advances in this exciting and emerging field, focussing
on protein engineering approaches that, together with
improved computational methods, hold promise to predict and
control protein aggregation linked to human disease, as well as
facilitating the manufacture of protein-based therapeutics.
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Introduction
It has been long been recognised that protein aggregation
pervades human morbidity and mortality [1] and
impinges on our ability to produce life-saving and life-
changing protein therapeutics both rapidly and economi-
cally [2]. It is now widely understood that as well as
adopting soluble, functional structures, many proteins
can also self-assemble forming structured aggregates such
as amyloid fibrils [3,4], or to undergo liquid-liquid phase-
separation [5,6]. The later process drives the formation of
membraneless organelles that can be functional (such as
in the nucleolus [7]), or causative of cellular dysfunctionwww.sciencedirect.com and disease (such as in virus replication [8] or in protein
aggregation disorders [9]) (Figure 1). The ability of
proteins to catalyse reactions, to form stable scaffolds,
and to bind ligands tightly and with high specificity, has
enormous potentials for the use of proteins in industry
[10,11]. However, a major challenge in the use of proteins
for such applications lies in their instability, conforma-
tional dynamics and inherent tendency to aggregate.
There is thus an important and currently unmet need
to be able to identify protein sequences that may have
undesired properties and to engineer their sequences to
improve their properties.
While aggregation-prone regions (APRs) can be readily
identified in short peptide segments using computer algo-
rithms [12–15], for intrinsically disordered proteins (IDPs)
and globular proteins it is still difficult, if not impossible, to
identify aggregation-prone and aggregation-resistant
sequences under a given set of conditions. This is because
aggregation (taken here to be any non-native oligomeric
state) can proceed through diverse mechanisms, driven by
distinct physico-chemical mechanisms (Figure 1). In addi-
tion, the observed aggregation propensity of each protein
sequence/structure on each pathway results from a com-
plex convolution of the effects of its sequence on thermo-
dynamic stability, structure, cooperativity and dynamics,
which all also depend on the solution conditions (pH,
temperature, ionic strength, solvent, nature of surfaces,
etc.). For each and all of the pathways traversed, detailed
understanding of the molecular mechanisms of the early
stages of aggregation remain elusive. By linking changes in
sequence to changes in biophysical and cellular behaviour,
powerful new approaches in protein engineering are now
able to provide a wealth of insight into this process, which
can then be used to enhance the performance of computer
algorithms so they are better able to predict protein
behaviour. Here we discuss how the integration of protein
engineering approaches with orthogonal methods includ-
ing computational and high-throughput phenotypic
screening methods, is now set to tackle this difficult
problem.
Delineating aggregation mechanisms using
rational protein engineering methods
Rational redesign (i.e. the substitution of a small number
of residues in a protein sequence with those having the
desired physico-chemical or spatial properties) is an
attractive approach to modulate protein aggregationCurrent Opinion in Structural Biology 2020, 60:157–166
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Figure 1
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Schematic illustration of aggregation pathways.
The precursor of aggregation may be the unfolded, partially folded or native state of a protein. During amyloid formation, oligomeric species
formed from the initial aggregation-prone monomer, can then assemble further to form higher-order oligomers, one or more of which can form a
nucleus, which, by rapidly recruiting other monomers, can nucleate assembly into protofibrils and amyloid fibrils. As fibrils grow, they can
fragment, yielding more fibril ends that are capable of elongation by the addition of new aggregation-prone species [86]. Alternatively, amorphous
aggregation can occur via one or more aggregation-prone species growing into larger species, by Ostwald ripening or other self-association
mechanisms [87].when there is prior knowledge of the mechanism of
aggregation (Figure 2) (e.g. by altering a protein–protein
interface required for aggregation [16–18]). Approaches
such as alanine scanning can also be used to identify or
confirm predictions of residues key to the control of
aggregation [19,20]. The ability to identify ‘aggregation
hotspots’ has been facilitated by the development of at
least 40 different algorithms [12–15]. While differing in
their metrics, these programs generally consider three
characteristics which control protein aggregation: solu-
bility, thermodynamic stability and aggregation propen-
sity. These computational tools, summarised in Table 1,
provide powerful information with which to start any
study of protein aggregation by portraying the inherent
aggregation propensity of the protein sequence. How-
ever, some consider local protein sequences (generally 4-
6 residues in length), leaving open the important ques-
tions of how this inherent insolubility/aggregation poten-
tial is realised in the context of the entire protein
sequence, whether disordered (as in the unfolded state
or for IDPs) or when ‘hidden’ by the native 3D structure
of the protein.
Detecting aggregation-prone regions in
primary sequences
More than 80 % of proteins possess at least one region in
their sequence that has a propensity to aggregate (i.e.Current Opinion in Structural Biology 2020, 60:157–166 APRs [21]), calculated based on hydrophobicity, charge
patterning, aromatic content and b-sheet propensity [12].
These algorithms use the primary amino acid sequence to
predict APRs via empirical training sets or/and calculation
based in the known physicochemical properties of the
20 canonical amino acids [12]. One of these algorithms,
TANGO [22] (Table 1), identifies APRs by calculating
the propensity of penta-peptide sequences to form buried
b-sheets, using an algorithm trained on experimental
measurement. In an exciting recent application of this
algorithm, Khodaparast et al. [23] identified APRs
enriched in the Escherichia coli proteome, and used the
resulting information to develop new antibacterial agents
by expression of redundant APRs (that were not sequence
unique in the genome). Expression of 125 of these
sequences resulted in cell death by inducing widespread
aggregation of 541 proteins (identified using mass spec-
trometry) into cross b-structure-enriched inclusion bod-
ies. In marked contrast, overexpression of unique APR
sequences within the proteome had no effect. Antimicro-
bial amyloid-nucleating peptides were bactericidal for a
large number of Gram-negative bacteria, suggesting that
the approach may have therapeutic potential. Similar
approaches from the same groups have also been used
as anti-cancer strategies [24], suggesting the general
utility of this method to exploit protein aggregation for
beneficial purposes.www.sciencedirect.com
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Figure 2
Current Opinion in Structural Biology
Summary of different methods for measuring and predicting protein aggregation.
Computational methods can predict aggregation-prone regions using sequence or structure input. Rational design involves introducing specific
mutations into a protein and subsequent analysis of the mutational effect in comparison to the behaviour of the wild-type protein. Directed
evolution and in vivo screening methods obviate protein purification and large numbers of variants can be screened to identify proteins with
enhanced properties. Finally, deep mutational scanning can potentially samples every possible mutation and enables quantification of the effect on
protein stability or aggregation to be determined in vivo.
www.sciencedirect.com Current Opinion in Structural Biology 2020, 60:157–166
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Table 1
Computational methods to predict and modulate protein aggre-
gation. Methods are grouped by calculated metric and are sub-
divided into methods that use primary or tertiary sequence data.
Algorithms denoted with ‘P’ represent those specific to Prion
formation.
Protein solubility
Sequence Structure
Aggrescan [88]
CamSol intrinsic [89]
Protein-Sol [90]
Proso II [91]
Aggrescan3D 2.0 [39]
CamSol [89]
SAP [92]
SOLart [93]
Aggregation propensity
Sequence Structure
Zyggregator [94]
TANGO [22]
Pafig [95]
SALSA [96]
WALTZ-DB 2.0 [97]
AmyCoP [98]
pWALTZP [99]
PrionWP [100]
PLAACP [101]
pRANKP [102]
PAPAP [103]
PASTA 2.0 [104]
Solubis [42]
FoldAmyloid [105]
NetCSSP [106]
BETASCAN [107]
STICHER [108]
Zipper DB [109]
AmyloidMutants [110]
AMYLPRED2 [111]Effect of ‘order’ in intrinsically disordered
proteins
Transient structure formed within IDPs and short peptides
can profoundly affect the observed aggregation rate of
APRs. For example, the aggregation of Tau, a largely
unstructured 441-residue protein which is associated with
severalneurodegenerativediseases, includingAlzheimer’s,
Pick and chronic traumatic encephalopathy [25–27], is
thought to be largely driven by the amyloidogenic six-
residue peptide sequence 306VQIVYK311 [28]. Perplex-
ingly, mutations genetically linked to tauopathies such as
P301L/S are found outside this sequence. This is similar to
the positional relationship between point variants of
a-synucleinassociated withearlyonset familialParkinson’s
disease and the non-amyloid component (NAC) region
shown to be necessary and sufficient for aggregation
[29,30]. Cross-linking studies, together with molecular
dynamics (MD) simulations, showed that residues 295-
311 of Tau form a b-hairpin, sequestering the APR, and
slowing aggregation. Accordingly, destabilising the b-hair-
pin (by substitution of P301 with a bulky leucine residue)
wastofoundtospeedupaggregation,whilestabilisingit (via
adding a Trp-zip motif to the termini of theb-hairpin, in the
P301Lbackground)sloweddownaggregation[28].These
elegant protein engineering experiments were thus able to
confirm b-hairpin formation as a controlling mechanism of
aggregation, in which the aggregation potential of the APR
is modulated by specific structure formation in a region that
both flanks and overlaps with the APR.Current Opinion in Structural Biology 2020, 60:157–166 The transient and often promiscuous intra-molecular
and inter-molecular interactions that control aggregation
of both IDPs and initially structured proteins are chal-
lenging to study, but are necessary to understand and
map because of their central importance in initiating
aggregation. As a consequence of their dynamic and
heterogeneous nature, high resolution structural techni-
ques to map these important protein–protein interac-
tions (Figure 1) are difficult, if not impossible to perform.
However, these sequences can be engineered to allow
site-specific introduction of specific reagents or reporters
to gain low resolution information. These include cross-
linking reagents, such as diazirines [31], ruthenium
complexes (PICUP) [32] and disuccinimidyl suberate
(DSS) [33], which when coupled with mass spectromet-
ric techniques [34], allow identification of pairs of resi-
dues that are spatially localised within the dynamic
ensemble, even if only transiently populated [35]. Other
reagents allow spectroscopic analyses. For example,
introduction of spin labels (introduced via unique Cys
residues) at single sites across proteins allows identifica-
tion of transient interactions between sequence-distant
residues, or between protein molecules using NMR
(using an approach known as Paramagnetic Relaxation
Enhancement [36]) or EPR (using Pulsed electron dou-
ble resonance (PELDOR)/double electron-electron res-
onance (DEER) EPR spectroscopy [37]. These methods
have been applied to a-synuclein, revealing that this
IDP makes extensive intra-molecular and inter-molecu-
lar contacts which are highly sensitive to environmental
conditions [29,37]. Such properties are reminiscent of
those described above for Tau, especially as early onset
familial missense variants occur outside of the main
amyloid core for both proteins, suggestive of similar
mechanisms at work that control the aggregation of these
IDPs in vitro and possibly also in vivo. Similarly to Tau,
formation of a b-hairpin structure (residues 37 to 54) in a
region upstream to NAC (residues 61-95) in a-synuclein,
induced upon complexation with a b-wrapin engineered
binding protein, resulted in inhibition of amyloid forma-
tion [38]. These methods often yield low resolution,
relatively sparse structural information, but by integrat-
ing the outputs from different approaches, remarkably
precise molecular mechanisms of aggregation can result,
especially when complemented with MD simulations.
For example, Bunce et al. [31] used fluorescence
quenching of an extrinsic fluorophore (TAMRA-Ahx)
and cross-linking studies to determine how the peptide
Ab16-22 (a fragment of Ab40/42 associated with
Alzheimer’s disease) aggregates and is able to catalyse
self-assembly of Ab40 via secondary surface nucleation.
Effect of ‘disorder’ in the aggregation of
globular proteins
Understanding the effect of protein dynamics, sequence
and solution conditions is also critically important for
determining, and hence predicting, the potential ofwww.sciencedirect.com
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occur from the native state, or from partially or globally
unfolded species (Figure 1), our ability to predict aggre-
gation requires understanding of the local and global
unfolding properties of the protein and how this depends
on sequence and solution conditions. Simulation (and
quantification) of protein dynamics in silico offers a solu-
tion to this problem, but requires greater computational
resources and, in some cases, development of force fields
able to accurately simulate protein behaviour. Aggres-
can3D 2.0 [39] (Table 1) addresses this issue by using
CABS-flex [40,41] for rapid simulations (10 nanoseconds
length) of near-native dynamics of globular proteins. This
‘dynamic mode’ of Aggrescan3D 2.0 yielded higher
aggregation propensity estimates for 80 % of the proteins
tested relative to the value obtained from static struc-
tures. An alternative approach is to integrate rapid compu-
tational methods to predict protein solubility with algo-
rithms able to predict thermodynamic stability. Solubis
[42,43] (Table 1), for example, combines TANGO [22]
(to identify APRs) with FoldX [44] (to compute the effect
of amino acid substitutions on thermodynamic stability).
Solubis [42,43] can be used to identify positions in a
protein structure able to accommodate gatekeeper resi-
dues (i.e. residues with low b-sheet propensity (e.g. Pro)
and high solubility such as the charged amino acids (Arg,
Lys, Glu and Asp) with minimal changes in protein
stability (DGUN). This allows the redesign of proteins
to retain stable and native folds, but to reduce aggregation
propensity. This approach has been used successfully to
decrease the aggregation kinetics of the Protective Anti-
gen protein from B. anthracis [42], a key component in
Anthrax vaccines [45], while preserving the native struc-
ture and function. This highlights the power of utilising
the interdependency of solubility, stability and aggrega-
tion propensity to determine and re-engineer a protein’s
aggregation potential.
Understanding the diverse effects of
electrostatics on protein aggregation
Proteins containing low complexity prion-like domains
(PRDs), typically IDPs enriched in glycine and hydrophilic
residues, play an important role in the formation of liquid-
liquid phase separated membrane-less organelles such as the
nucleolus, stress granules and P-bodies [46], and may allow
generation of selectable genetic variability akin to that
previously reported for prions [47]. Despite the relative
depletion of hydrophobic residues in PRDs, reversible amy-
loid fibril formation can occur upon liquid-liquid phase
separation of such sequences, and hence these sequences
are known as LARKS (low-complexity aromatic-rich kinked
segments) [48]. One such example is hnRNPA1 [49], an
RNA binding protein in which missense mutations are
associated with neurodegenerative diseases [50]. Scanning
the low complexity (LC) domains for segments containing
(Asn)-Asp-(Asn) and (Gly)-Phe/Tyr-(Gly)  motifs identified
three peptides which formed a hydrogel composed ofwww.sciencedirect.com amyloid fibrils that dissociated upon an increase in temper-
ature [49]. The structure of the first reversible amyloid core
(termed hnRAC1) revealed the cross-b architecture
expected for an amyloid fibril, but with notable differences,
thought to be important for their function. Firstly, the inter-
sheet interface was composed of hydrophilic Asn residues
compared with the dry steric zipper typical of amyloid [3,4].
The fibre was further destabilised by the stacking of an
aspartic acid (D214) along the exterior face of its parallel in-
register b-sheets. Finally, the structure revealed a kink at
G211, thought to allow hydrogel formation by sterically
facilitating inter-fibrillar cross-linking via p-p stacking of
the adjacent Phe and other residues. Accordingly, an
hnRAC1 peptide containing G211V, or F210A, or F216A
displayed reversible fibril formation, but impaired hydrogel
formation. Conversely substituting the destabilising aspartic
acid residue (D214V/N) in hnRAC1 resulted in irreversible
fibril formation. Interestingly, Asp, Val or Asn substitutions
are also found in familial amyotrophic lateral sclerosis (ALS)
patients and result in irreversible fibril formation [51]. Taken
together, the results provide a structural rationale for
‘maturation’ of irreversible amyloid fibrils within liquid-
liquid phase separated low complexity PRDs. The recogni-
tion that the aggregation propensity (and liquid-liquid de-
mixing) of PRDs is driven by sequences that are chemically
and sterically distinct to those involved in amyloid formation
[52]has ledtothedevelopmentofAMYCO[53]analgorithm
specialised for the prediction of PRDs (Table 1).
Electrostatic interactions are also important drivers and
modulators of the aggregation of globular proteins, with
pH and ionic strength being important determinants of
aggregation both by increasing the probability of proteins
unfolding, and by changing the probability of productive
protein–protein interactions between transiently exposed
APRs in non-native states [54–56]. The aggregation of
natively structured proteins can also be problematic for
proteins producedat scale, such as in the biopharmaceutical
industry in which proteins are manufactured in high vol-
ume and at high concentration [2]. In these cases, aggrega-
tion is reversible (at least in the initial stages) and is driven
by intermolecular contacts mediated by the presence of
hydrophobic or charge-complemented patches on the pro-
tein surface, via a mechanism referred to as ‘colloidal
aggregation’ [57] (Figure 1). ‘Supercharging’ proteins by
introductionofan excessof acidicor basic residues through-
out the protein [58–60] has been shown to reduce aggrega-
tion induced by such pathways. Alternatively, introducing
defined clusters of specific charged residues that enhance
protein stability and reduce protein–protein interactions
has been shown to be an effective strategy to reduce
aggregation [59,61–63].
Using directed evolution and in vivo screening
to define aggregation landscapes
Directed evolution (DE) methods involve generating
diversity in the gene of interest and then isolating variantsCurrent Opinion in Structural Biology 2020, 60:157–166
162 Proteinswith improved characteristics from this library using
phenotypic selection [64] (Figure 2). DE approaches have
been used to develop aggregation-resistant biopharma-
ceuticals by screening for thermal resistance [65,66], or by
utilising three selection methods (temperature, reduction
and hydrophobicity) in parallel [67]. A potential disad-
vantage of optimising a protein’s sequence in this manner
is that function is ignored, which can result in proteins
with enhanced biophysical properties, but reduced activ-
ity, akin to sequence-stability trade-offs [68]. To counter
this, Wang et al. described a soluble expression phage
assisted continuous evolution method (SE-PACE) [69].
Here, the protein of interest (POI) is linked in-frame to
the N-terminal fragment of a split T7 RNA polymerase
(to select for soluble POIs), as well as to the omega
subunit of RNA polymerase (RNAP) to select for POIs
with high target binding affinity using a bacterial two
hybrid approach (using 434 phage cI repressor as the
DNA-binding domain). Linking expression of soluble
and functional POI to these distinct polymerases allowed
both traits to be selected for simultaneously by only
allowing expression of the minor coat protein III (pIII)
required for progeny phage upon expression and comple-
mentation of both the N-terminal and C-terminal frag-
ments of an intein transcribed by RNAP and T7 poly-
merase, respectively. Using this approach, a fivefold
enhancement of expression, but unchanged target affinity
was achieved for single-chain antibody fragments (scFvs),
as well as enhancement of both expression and activity for
the enzyme cytidine deaminase.
If aggregation occurs via a partially folded protein structure,
the propensity to aggregate may not always correlate with
protein thermal stability. For such proteins, it is necessary
to develop alternative screens to create proteins with
enhanced solution behaviour. One route to achieve this
has recently been developed, in which an E. coli b-lacta-
mase folding reporter links the innate ability of a protein to
aggregate to antibiotic sensitivity by fusing the POI
between two domains of b-lactamase [70,71]. The system
has been shown to be able to differentiate between aggre-
gation-prone and aggregation-resistant variants of diverse
protein sequences and structures, including the aggrega-
tion-prone peptides Ab1-42 and amylin, the aggregation-
prone protein b2 microglobulin, and single domain anti-
bodies. The system has also been used to screen for small
molecule inhibitors of protein aggregation in the periplasm
of E. coli [71] and for the selection of excipients able to
suppress aggregation [72]. Other screens that link survival
to dihydrofolate reductase (DHFR) activity have also been
developed and used to identify peptide inhibitors of
a-synuclein aggregation [73] and to characterise the phe-
notypes of 99 % of all the possible single-site substitutions
of Ab1-42 (see below) [74].
Screening peptides in vivo has also been used to gain
deeper insight into the pathways by which toxicCurrent Opinion in Structural Biology 2020, 60:157–166 aggregates are formed [75]. A combinatorial library of
>10 million short cyclic peptides (S/T/C-X1-Xn, where X
is any amino-acid and n = 3-5) was produced in bacteria
using split intein-mediated circular ligation of peptides
and proteins [76]. The peptides were then screened for
their ability to reduce aggregation monitored by a reduc-
tion in fluorescence of an Ab1-42-GFP fusion reporter by
fluorescence-activated cell sorting [75]. Biochemical
analysis of clones that increased fluorescence revealed
penta-peptides that halt Ab1-42 aggregation by stabilising
b-sheet-like structures. These peptides also reduced
toxicity measured in primary neuronal cell lines and in
vivo.
Developing enhanced understanding of
protein behaviour using deep mutational
scanning
Deep mutational scanning (DMS) can be used to reveal
the effect of thousands of different single amino-acid
substitutions on a protein’s properties by quantifying
the relative change of abundance of each member of
the library under a suitable selective pressure using next
generation sequencing methods [77]. This approach is
extremely powerful as it combines the strengths of both
‘traditional’ protein engineering methods (quantifiable
sequence-phenotype relationships) and DE methods
(the ability search vast areas of sequence space without
protein purification) (Figure 2). DMS has thus found
broad application from structure determination [78,79]
to developing a better understanding of the determinants
of protein thermodynamic stability [80] and even the
utility of alanine scanning [81].
Two studies have recently used DMS to gain a broader
understanding of the relationship between sequence and
aggregation mechanism. Firstly, to investigate the molec-
ular determinants of Ab1-42 aggregation Gray et al., [74],
used selective growth pressure in yeast cells, by fusing Ab1-
42 to DHFR and growing a library of Ab1-42 variants using
methotrexate as a selective pressure for DHFR function.
This screen evaluated 791/798 of all possible single amino
acid substitutions of Ab1-42. Remarkably, 25 % of the
variants were more soluble than Ab1-42, with the others
showing unchanged or increased aggregation propensity.
Substitutions to Asp and Pro enhanced solubility the most
(presumably by increasing charge or decreasing b-strand
propensity, respectively), whereas substitutions with Trp
or Phe were associated with greater aggregation (presum-
ably by increasing hydrophobicity). This mutational infor-
mation revealed residues 17-20, 31-32, 34-35, 39 and 41 as
‘hotspots’ important for Ab1-42 aggregation, which most
likely form buried b-strands. Interestingly, these concur
with predictions of APRs, for example, using TANGO and
Zyggregator [82]. In the second example, Bolognesi et al.
exploited the ability to measure the sequence-function
relationships of thousands of variants in parallel to under-
stand the relationship between aggregation and toxicitywww.sciencedirect.com
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(TDP-43), the aggregation of which is linked to ALS [83].
Comparison of the relative change in the population of
>50 000 variants of yeast cells containing one or two
substitutions in TDP-43 before and after induction
revealed a 31 residue ‘toxic hotspot’, which correlates with
the region of the protein in which mutations occur in
ALS patients. Surprisingly, substitutions in this hotspot
that increase hydrophobicity decreased toxicity, whereas
substitutions that increase charge or polarity increased
toxicity. Variants with increased hydrophobicity produced
larger, stable aggregates that are less toxic than the small
liquid-like loci found at the nuclear periphery for the more
toxic variants. Furthermore, epistatic analysis of variants
containing two substitutions suggested the presence of
secondary structure in this apparently disordered domain.
This powerful method can thus be used to identify the
structural properties of IDPs in vivo and, further, to inter-
rogate the relationship between the function and toxicity of
amyloid versus protein assemblies in liquid-liquid phase
separation.
Future perspectives
The synergy between protein engineering and biophys-
ical measurements in vitro with cellular approaches has
been integral to developing our understanding of pro-
tein aggregation (Figure 2). The diversity of aggregates
and aggregation mechanisms, together with the emerg-
ing realisation that even IDPs contain transient struc-
ture crucial to their function and aggregation potentials,
and the finding that native state dynamics are crucial to
understanding aggregation propensity, pose enormous
current challenges to our ability to predict and modu-
late aggregation. The ability to rapidly survey the
aggregation propensity of large numbers of highly
homologous sequences using DMS methods together
with statistical and machine learning methods, is now
able to guide protein engineering [84,85] and, in the
future, is sure to guide the development of new predic-
tive algorithms. These large datasets, when integrated
with detailed spectroscopic and cross-linking studies
(all made possible by protein engineering approaches),
MD simulations and cellular insights, will allow us in
the future to define the relationship between sequence,
structure, function and aggregation. This will allow
genome engineering or the development of small mole-
cules or biomolecules able to control protein aggrega-
tion and to develop and manufacture biotherapeutics
more rapidly and economically. What is clear is that
there is still much to learn, but the powers of modern
protein engineering methods, combined with the abil-
ity to harness the information that results through
machine learning, promises a step change into our
ability to understand protein behaviour and to capital-
ise on the new knowledge to capture the complexity
and powers of proteins for the benefits of humankind.www.sciencedirect.com CRediT author statement
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